Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
m |
m |
||
Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
+ | *[[Bladder cancer]] | ||
*[[Esophageal squamous cell carcinoma]] | *[[Esophageal squamous cell carcinoma]] | ||
+ | *[[Hepatocellular carcinoma]] | ||
+ | *[[Hodgkin lymphoma]] | ||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
Line 17: | Line 20: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
+ | [[Category:Bladder cancer medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
+ | [[Category:Hepatocellular carcinoma medications]] | ||
+ | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] |
Revision as of 21:21, 6 February 2023
Note: Tislelizumab is approved in China for multiple indications, but does not appear to have a brand name at this time.
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Bladder cancer
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
Also known as
- Code name: BGB-A317
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Bladder cancer medications
- Esophageal cancer medications
- Hepatocellular carcinoma medications
- Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- NMPA approved drugs